Infiltration of the heart with the protein transthyretin (TTR) commonly leads to the development of cardiomyopathy (ATTR-CM) and heart failure. Once considered rare, advancements in testing have led to the finding that ATTR-CM is much more prevalent. However, no current data exists in a Canadian population. Therefore, this project will determine the how prevalent ATTR-CM is in patients undergoing cardiac surgery at the New Brunswick Heart Center (NBHC). Furthermore, we will determine whether ATTR-CM is associated with worsened outcomes, including mortality, following an intervention.